secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001213900-25-026322
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies reports FY2024 net operating loss of $10.9M; cash runway into 2026
-------------------------------------------------------------------------------

- Net operating loss $10.886M in 2024 vs $7.916M in 2023, driven by IPO costs.
- Net loss per share $0.88 on 12.38M shares vs $1.46 on 5.43M shares in 2023.
- Cash on hand expected to last into 2026 due to reduced burn rate starting Q2 2025.
- Full Phase 2b OST-HER2 data to be presented June 2025; BLA submission targeted for year-end 2025.
- Plans to divest anticipated Priority Review Voucher (PRV) from potential BLA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/0001213900-25-026322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/ea0236436-8k_ostherapi.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-026322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer